LSTA201 / Lisata Therapeutics - LARVOL DELTA

CLBS201 in Patients With Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - P1 | N=6 | Completed | Sponsor: Lisata Therapeutics, Inc. | Active, not recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

A Proof-of-Concept Study of CD34+ Cell Therapy for Diabetic Kidney Disease (KIDNEY WEEK 2022) - "There will be pauses after the first and second subjects’ Day 15 visit to review data for safety before proceeding with further exposures Results The study was initiated in December 2021 and is expected to complete enrollment mid-2022. Information on study status, baseline demographics, and up-to-date observations will be presented Conclusion CLBS201 cell therapy may be a promising treatment strategy for diabetic kidney disease"

Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Peripheral Arterial Disease • Renal Disease • Transplantation • Type 2 Diabetes Mellitus • CD34 • CSF3